#Benchmark research reviews series#

#Benchmark research reviews series#

The Expert Committee meeting follows a series of internal reviews by the Research Team to confirm data quality as well as discussions with external stakeholders and experts working in AMR. The process centres on building consensus among experts on where pharmaceutical companies have potential for making the biggest change on global health priorities. The meeting is a milestone in the in-depth methodology review process developed by the Foundation. The Benchmark Research Team has developed the methodology proposals based on internal reviews of the metrics and discussions with external stakeholders. Joakim Larsson (University of Gothenburg) Gregory Frank (Biotechnology Innovation Organization) They join six current members of the Committee: Margareth Ndomondo-Sigonda (African Union-NEPAD Planning & Coordinating Agency)Īndrew Singer (NERC Centre for Ecology & Hydrology) In 2018, the Foundation welcomes three new members: The Committee is Chaired by Professor Hans Hogerzeil (University of Groningen). They each bring to the table an essential perspective on pharmaceutical company activity regarding access to medicine and antimicrobial resistance (AMR). In 2018, the EC is made up of ten independent experts, including from World Health Organization (WHO), top-level academic centres, governments in low- and middle-income countries, investors and pharmaceutical industry representatives. The role of the Expert Committee is to provide independent strategic guidance during the methodology development process. With such a variety of viewpoints around the table, I’m looking forward to a day of rich discussions about the priorities for pharma company action on AMR.”- Gabrielle Breugelmans, Director of Research at the Access to Medicine Foundation. “ It’s fantastic to be bringing this team of experts together in Amsterdam to talk about the Benchmark. We are also looking at new ways to credit companies that target the most resistant pathogens where new treatments are urgently needed. For example, Committee members will explore the role of generic medicine manufacturers in AMR surveillance with the Foundation’s Research Team, as well as new ways of measuring how companies ensure they meet manufacturing quality requirements.

The proposals on the agenda relate to reaffirming the rigour of the Benchmark methodology, while facilitating trend analysis between Benchmarks.